Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Jiřı́ Mayer(University Hospital Brno), Branimir Jakšić(Leeds Teaching Hospitals NHS Trust), Tadeusz Robak(Medical University of Lodz), Jingyang Wu(Leeds Teaching Hospitals NHS Trust), Cynthia A. Sirard(Leeds Teaching Hospitals NHS Trust), Aleksander B. Skotnicki(Leeds Teaching Hospitals NHS Trust), Anna Dmoszyńska(1 Military Clinical Hospital with Outpatient Clinic)
Journal of Clinical Oncology
November 5, 2007
10.1200/jco.2007.12.9098
Cited by 556

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k